Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTSHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DRTS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.09B
- EPS (TTM)
- -$1.04
- Dividend yield
- None
- 52-week range
- 3.65 – 15.79
- Day range
- 11.32 – 12.19
- Volume / Avg
- 626.87K / 591.88K
- Beta
- —
- Shares outstanding
- 92.48M
52-week range
DRTS stock today
On Nov 20, DRTS ended the session at $11.76, adding $0.445 (3.93%), versus the S&P 500's 3.70% decline. Shares are 25.6% below their 52-week high of $15.79, set on Sep 17, 2026 and 222.1% above the 52-week low of $3.65, in the middle of the past year's range. DRTS is up 137.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 207.7%.
Alpha Tau Medical has posted a net loss over the last twelve months (EPS of -$1.04), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Alpha Tau Medical
Company profileAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Uzi Sofer
- Headquarters
- Jerusalem
- Employees
- 121
- Website
- alphatau.com
Financial highlights
Full financialsAlpha Tau Medical reported a net loss of $42.6 million, compared with a loss of $31.8 million a year earlier. Diluted earnings per share came in at -$0.53.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-42.63M | $-31.75M | $-29.16M | $-33.76M | $-27.27M |
| EPS (diluted) | $-0.53 | $-0.45 | $-0.42 | $-0.53 | $-0.67 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$20.60+75.24%
- Strong buy 2
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 19, 2026
- EPS actual vs est.
- $-0.14 vs $-0.15
- Surprise
- +6.67%
DRTS news
All DRTS news- Alpha Tau Medical GAAP EPS of -$0.39Seeking Alpha
- Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- Why is Alpha Tau Medical stock surging today?Investing.com
- Alpha Tau Reports Positive Data From Alpha DaRT Recurrent Glioblastoma Trial; Shares RiseNasdaqDRTS, ET
- Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious AdverGlobeNewswire
- Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN TrialGlobeNewswire
- Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock ExchangeGlobeNewswire
- Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in KoreaGlobeNewswire
Alpha Tau Medical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SIBNSI-BONE Inc. | 23.73 | -0.08% | $1.07B | vs DRTS |
| IRMDiRadimed Corporation | 81.02 | -0.30% | $1.04B | vs DRTS |
| IARTIntegra LifeSciences Holdings Corporation | 13.25 | -2.21% | $1.03B | vs DRTS |
| ATECAlphatec Holdings Inc. | 6.68 | -3.19% | $1.02B | vs DRTS |
| SGPSpyGlass Pharma Inc. | 30.43 | -1.14% | $1.02B | vs DRTS |
| TNDMTandem Diabetes Care Inc. | 17.46 | +3.93% | $1.22B | vs DRTS |
| NVCRNovoCure Limited | 10.71 | +0.19% | $1.25B | vs DRTS |
| AORTArtivion Inc. | 18.16 | -2.00% | $886.02M | vs DRTS |
Indexes, lists and sector
Alpha Tau Medical stock FAQ
What is Alpha Tau Medical's stock price today?
DRTS last traded at $11.76 as of Nov 20, 4:00 PM EST, up 3.93% on the day. Prices are delayed at least 15 minutes.
Who is Alpha Tau Medical's CEO?
Mr. Uzi Sofer is the chief executive officer of Alpha Tau Medical Ltd., which has about 121 employees.
What is the DRTS 52-week high?
The 52-week high for DRTS is $15.79 and the 52-week low is $3.65. The stock is currently 25.6% below its high.